U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06863467) titled 'Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.' on Feb. 21.
Brief Summary: Gemini is being evaluated in a placebo controlled, single dose, escalating dose study to evaluate the safety and tolerability of intravenous Gemini in adult subjects with stage 3 or 4 chronic kidney disease. Pharmacokinetics will be evaluated and measurements of the effect of Gemini on pharmacodynamic activity will be measured to assess changes in potential pharmacodynamic markers.
Study Start Date: Jan. 20
Study Type: INTERVENTIONAL
Condition:
Renal Insufficiency, Chronic
Chronic Kidney Disease stag...